{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:36:38Z","timestamp":1792787798074,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Jinka University","id":[{"id":"https:\/\/ror.org\/05gt9yw23","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13915-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:53:25Z","timestamp":1782928405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver function impairment and associated factors among adult human immunodeficency virus infected individuals on antiretroviral therapy at Hosanna town, Central Ethiopia"],"prefix":"10.1186","volume":"26","author":[{"given":"Sisay","family":"Abebe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerihun","family":"Ataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemal","family":"Husen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desalegn Admassu","family":"Ayana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"13915_CR1","unstructured":"Shani Saks D, MS FACOL. Hepatic Impairment. 2022. Available from: https:\/\/healthmatch.io\/liver-disease\/hepatic-impairment."},{"issue":"1","key":"13915_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2014.09.001","volume":"19","author":"C Acharya","year":"2015","unstructured":"Acharya C, Dharel N, Sterling RK. Chronic liver disease in the human immunodeficiency virus patient. Clin Liver Dis. 2015;19(1):1\u201322.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"13915_CR3","first-page":"87","volume":"25","author":"J Navarro","year":"2022","unstructured":"Navarro J. HIV and liver disease. AIDS Rev. 2022;25(2):87\u201396.","journal-title":"AIDS Rev"},{"issue":"1","key":"13915_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-022-07838-w","volume":"22","author":"O Mohammed","year":"2022","unstructured":"Mohammed O, Alemayehu E, Bisetegn H, Tilahun M, Gedefie A, Ebrahim E, et al. Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):1\u201314.","journal-title":"BMC Infect Dis"},{"key":"13915_CR5","unstructured":"Nduka DS. Consequences of liver damage: a comprehensive overview. Physionyx. 2026. Available from: https:\/\/physionyx.com\/articles\/consequences-of-liver-damage-overview\/."},{"issue":"2","key":"13915_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u201337.","journal-title":"J Hepatol"},{"key":"13915_CR7","doi-asserted-by":"crossref","unstructured":"Navarro J. HIV and liver disease. AIDS Rev. 2022;24(2).","DOI":"10.24875\/AIDSRev.M22000052"},{"key":"13915_CR8","unstructured":"Cleveland Clinic. Liver failure. Cleveland (OH): Cleveland Clinic; 2023. Available from: https:\/\/my.clevelandclinic.org\/health\/diseases\/17819-liver-failure."},{"issue":"1","key":"13915_CR9","first-page":"e000166","volume":"4","author":"MB Kaspar","year":"2017","unstructured":"Kaspar MB, Sterling RK. Mechanisms of liver disease in patients infected with HIV. Br Med journalOpen Gastroenterol. 2017;4(1):e000166.","journal-title":"Br Med journalOpen Gastroenterol"},{"key":"13915_CR10","unstructured":"Wilberg M. HIV treatment and drug-drug interactions [Internet]. London: Aidsmap; 2024 [updated 2024 Feb]. Available from: https:\/\/www.aidsmap.com\/about-hiv\/hiv-treatment-and-drug-drug-interactions#:~:text=Many%20people%20with%20HIV%20need,share%20the%20same%20metabolic%20pathway."},{"key":"13915_CR11","unstructured":"NHS. Assessing liver function and interpreting liver blood tests United Kingdom: National Health Service of United Kingdom. 2024 [Available from: https:\/\/www.sps.nhs.uk\/articles\/assessing-liver-function-and-interpreting-liver-blood-tests."},{"key":"13915_CR12","unstructured":"Minter VLMZDA. Liver Function Tests. July 30, 2023: National Center for Biotechnology Information; 2025."},{"key":"13915_CR13","unstructured":"David M. Liver Function Tests USA. 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482489\/."},{"issue":"3","key":"13915_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4314\/ejhs.v26i3.4","volume":"23","author":"W Mulu","year":"2013","unstructured":"Mulu W, Gidey B, Chernet A, Alem G, Abera B. Hepatotoxicity and associated risk factors in HIV-infected patients receiving antiretroviral therapy at Felege Hiwot Referral Hospital, Bahirdar, Ethiopia. Ethiop J health Sci. 2013;23(3):217\u201326.","journal-title":"Ethiop J health Sci"},{"key":"13915_CR15","doi-asserted-by":"crossref","unstructured":"Shiferaw MB, Tulu KT, Zegeye AM, Wubante AA. Liver enzymes abnormalities among highly active antiretroviral therapy experienced and HAART na\u00efve HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: a comparative cross-sectional study. AIDS Res Treat. 2016;2016.","DOI":"10.1155\/2016\/1985452"},{"issue":"1","key":"13915_CR16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s13104-019-4748-4","volume":"12","author":"E Tesfa","year":"2019","unstructured":"Tesfa E, Siefu D, Belayneh Y, Mekonnen Z. Liver enzyme elevation in patients taking HAART compared with treatment na\u00efve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia. BMC Res Notes. 2019;12(1):714.","journal-title":"BMC Res Notes"},{"key":"13915_CR17","first-page":"1","volume":"13","author":"A Zeleke","year":"2020","unstructured":"Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital. Ethiopia BMC Res notes. 2020;13:1\u20135.","journal-title":"Ethiopia BMC Res notes"},{"issue":"1","key":"13915_CR18","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.4102\/sajhivmed.v24i1.1522","volume":"24","author":"J Horak","year":"2023","unstructured":"Horak J, Venter WD, Wattrus C, Papavarnavas N, Howell P, Sorour G, et al. Southern African HIV clinicians Society 2023 Guideline for post-exposure prophylaxis: updated recommendations. South Afr J HIV Med. 2023;24(1):1522.","journal-title":"South Afr J HIV Med"},{"key":"13915_CR19","unstructured":"DAIDS. Division of AIDS (DAIDS.) Table for Grading the Severity of Adult and Pediatric Adverse Events: USA; 2017 [Available from: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"key":"13915_CR20","unstructured":"World Health Organization. Global status report on alcohol and health 2018. World Health Organization; 2018."},{"key":"13915_CR21","unstructured":"World Health Organization. WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke. World Health Organization; 2023."},{"key":"13915_CR22","unstructured":"WHO. WHO traditional medicine strategy 2014\u20132023, World Health Organization. 2013. Available from: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/16362a42-6583-4601-a7da-d0ed6bc39108\/content."},{"key":"13915_CR23","doi-asserted-by":"crossref","unstructured":"Gebremicael G, Tola HH, Gebreegziaxier A, Kassa D. Incidence of hepatotoxicity and factors associated during highly active antiretroviral therapy in people living with HIV in Ethiopia: a prospective cohort study. HIV AIDS (Auckl). 2021:329\u201336.","DOI":"10.2147\/HIV.S283076"},{"issue":"02","key":"13915_CR24","first-page":"275","volume":"39","author":"Y Jun","year":"2019","unstructured":"Jun Y, Qianlei X, Xiumin C, Pengfei M, Qingya L, Liran X, et al. Prevalence of liver injury among patients with acquired immunodeficiency syndrome treated with highly active antiretroviral therapy in China. J Tradit Chin Med. 2019;39(02):275.","journal-title":"J Tradit Chin Med"},{"issue":"4","key":"13915_CR25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/labmed\/lmaa106","volume":"52","author":"T Hashempour","year":"2021","unstructured":"Hashempour T, Moayedi J, Mousavi Z, Esmaeli M, Asadzadeh A, Hasanshahi Z, et al. Incidence of Hepatotoxicity in Iranian Patients With HIV on Antiretroviral Therapies and Its Correlation with Virologic Response to HIV Treatment. Lab Med. 2021;52(4):369\u201374.","journal-title":"Lab Med"},{"issue":"6","key":"13915_CR26","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1128\/JVI.80.6.2797-2807.2006","volume":"80","author":"P Meuleman","year":"2006","unstructured":"Meuleman P, Libbrecht L, Wieland S, De Vos R, Habib N, Kramvis A, et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol. 2006;80(6):2797\u2013807.","journal-title":"J Virol"},{"key":"13915_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2334-5-58","volume":"5","author":"C Torti","year":"2005","unstructured":"Torti C, Lapadula G, Casari S, Puoti M, Nelson M, Quiros-Roldan E, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BioMed Cent Infect Disease. 2005;5:58.","journal-title":"BioMed Cent Infect Disease"},{"issue":"4","key":"13915_CR28","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1530-0277.2006.00084.x","volume":"30","author":"FT Crews","year":"2006","unstructured":"Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, et al. Cytokines and alcohol. Alcohol Clin Exp Res. 2006;30(4):720\u201330.","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"13915_CR29","first-page":"229","volume":"33","author":"S Barve","year":"2010","unstructured":"Barve S, Kapoor R, Moghe A, Ramirez JA, Eaton JW, Gobejishvili L, et al. Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV-infected patients. Alcohol Res Health. 2010;33(3):229\u201336.","journal-title":"Alcohol Res Health"},{"key":"13915_CR30","unstructured":"John USA. Hopkins University; 2024. Available from: https:\/\/www.hopkinsmedicine.org\/health\/conditions-and-diseases\/alcoholinduced-liver-disease."},{"key":"13915_CR31","doi-asserted-by":"crossref","unstructured":"Kwofie TB, Adigbli D, Osei-Yeboah J, Ativi E, Lokpo SY. Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity. Heliyon. 2021;7.","DOI":"10.1016\/j.heliyon.2021.e07172"},{"issue":"5","key":"13915_CR32","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1086\/317449","volume":"31","author":"EH Gisolf","year":"2000","unstructured":"Gisolf EH, Dreezen C, Danner SA, Weel JLF, Weverling GJ. Risk Factors for Hepatotoxicity in HIV-1\u2014Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine. Clin Infect Dis. 2000;31(5):1234\u20139.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"13915_CR33","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/hepr.12523","volume":"46","author":"L-S Qu","year":"2016","unstructured":"Qu L-S, Zhang H-F. Significance of viral status on prognosis of hepatitis B-related hepatocellular carcinoma after curative resection in East Asia. Hepatol Res. 2016;46(1):40\u20139.","journal-title":"Hepatol Res"},{"issue":"4","key":"13915_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/2384-5147.144727","volume":"1","author":"M Hamza","year":"2014","unstructured":"Hamza M, Maifada YA, Musa B, Mijinyawa MS, Muhammad BM, Garba HA. Prevalence and risk factors for hepatotoxicity among patients with HIV\/AIDS on highly active antiretroviral therapy in North-Western Nigeria. Sub-Saharan Afr J Med. 2014;1(4):175.","journal-title":"Sub-Saharan Afr J Med"},{"issue":"19","key":"13915_CR35","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4254\/wjh.v7.i19.2189","volume":"7","author":"E Stournaras","year":"2015","unstructured":"Stournaras E, Tziomalos K. Herbal medicine-related hepatotoxicity. World J Hepatol. 2015;7(19):2189\u201393.","journal-title":"World J Hepatol"},{"issue":"1","key":"13915_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13104-019-4872-1","volume":"13","author":"A Zeleke","year":"2020","unstructured":"Zeleke A, Misiker B, Yesuf TA. Drug-induced hepatotoxicity among TB\/HIV co-infected patients in a referral hospital, Ethiopia. BMC Res Notes. 2020;13(1):2.","journal-title":"BMC Res Notes"},{"key":"13915_CR37","doi-asserted-by":"publisher","first-page":"817370","DOI":"10.3389\/fmed.2022.817370","volume":"9","author":"S Liu","year":"2022","unstructured":"Liu S, Zhou Y, Wang Y, Li CB, Wang W, Lu X, et al. The Correlated Risk Factors for Severe Liver Damage Among HIV-Positive Inpatients With Abnormal Liver Tests. Front Med. 2022;9:817370.","journal-title":"Front Med"},{"key":"13915_CR38","first-page":"47","volume":"65","author":"S Bajpai","year":"2017","unstructured":"Bajpai S, Joshi K. Hepatotoxicity in HIV patients: an observational study in patients from tertiary care centre of Western India. J Assoc Physicians India. 2017;65:47.","journal-title":"J Assoc Physicians India"},{"issue":"9","key":"13915_CR39","first-page":"688","volume":"49","author":"OA Marzuki","year":"2008","unstructured":"Marzuki OA, Fauzi AR, Ayoub S, Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singap Med J. 2008;49(9):688\u201393.","journal-title":"Singap Med J"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13915-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13915-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:59:05Z","timestamp":1790117945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13915-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13915"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13915-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"20 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The declaration of Helsinki was followed in conducting this study and ethical clearance was obtained from Haramaya University, College of Health and Medical Sciences, Institutional Health Research Ethics Review Committee (Reference number: IHRERC\/214\/2023). Additionally, informed, voluntary, written, and signed consent was obtained from the head of the Wachamo University Nigist Eleni Mohammed Memorial Comprehensive Specialized Hospital. Each participant received detailed information on the study\u2019s purpose, procedures, potential risks, and benefits. Additionally, participants were made aware of their freedom to leave the study at any time without facing any consequences. All study participants in this study provide informed, voluntary, written and signed consent prior to their involvement. To ensure the confidentiality of the data, the study participants were identified via codes, and unauthorized persons were not able to access the collected data. In addition, the clinical specimens collected during the study period were used for the stated objectives only. Abnormal findings are reported to facilitate improved clinical management, as ignoring such results would be ethically inappropriate, in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1702"}}